The leading Danish pharmaceutical company, Novo Nordisk, is planning to implement AI technology OpenAI in all its structural divisions to speed up the development process of medicines, as reported by Bloomberg.

The parties do not disclose the financial details of the agreement. The new partnership will complement the company’s existing AI projects, including collaboration with Nvidia in research. The goal is to accelerate the process from invention to planning release and regain lost ground in the obesity segment, where US drug company Eli Lilly & Co. has taken over leadership.

CEO Mike Daustdar emphasized that the deal with OpenAI is not intended to replace scientists or staff. By contrast, AI is designed to improve performance in a short way: find biological targets faster, optimize clinical trials, and draw clear conclusions from accumulated data sets.

Pilot launches are launched in research and development departments, on production sites and in the commercial unit. Full-scale integration is scheduled for the end of 2026.